English

SALARIUS PHARMACEUTICALS, INC.

EDGAR

DCOY Registration statement (S-1) · filed 2026-10-07

70 filing records in this dataset, filed from 2014-12-29 to 2026-10-07. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

228 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 227629 USD Source

Operating margin

-1,155.84%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -2631021 USD Source
Revenue: 227629 USD Source

Operating cash flow

-2.65 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -5541348 USD Source
Operating Cash Flow: -2889329 USD Source

Cash and cash equivalents: 8.29 million USD 2026-06-30 Source
Exact value

8289108 USD
Long-term debt including current maturities: Not available
Shares outstanding: 532 thousand shares 2026-06-30 Source
Exact value

531968 shares

Reported share-count change

-74.99% · -1.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

2127286 shares · 2025-06-30· Source
531968 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-14.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -873467 USD · 2025-07-01 – 2025-09-30 Source
Net income: -12518480 USD · 2025-01-01 – 2025-12-31 Source
Net income: -3540825 USD · 2025-01-01 – 2025-09-30 Source
Net income: -2224628 USD · 2026-01-01 – 2026-03-31 Source
Net income: -2373800 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-8.32 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -3690700 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2044011 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -4827188 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -3690700 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2889329 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -5541348 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -2889329 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

0 USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Capital expenditure: 0 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 0 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 0 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 0 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 0 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 0 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 0 USD · 2018-01-01 – 2018-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-07.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2022-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2021-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 6.94 million

Prior period

−USD 5.58 million

2024-01-01 – 2024-12-31
Current period

−USD 12.52 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-12518480 − -5575777 = -6942703 USD

-5575777 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-12518480 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SALARIUS PHARMACEUTICALS, INC. · 2025-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Year-over-year change in Net income: -6942703 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -12518480 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1543807 Filing: 000119312526134897 Input fundies:NetIncome: -5575777 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1488956 Filing: 000119312526134897
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 301,851

Prior period

−USD 4.53 million

2024-01-01 – 2024-12-31
Current period

−USD 4.83 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-4827188 − -4525337 = -301851 USD

-4525337 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-4827188 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SALARIUS PHARMACEUTICALS, INC. · 2025-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Year-over-year change in Operating cash flow: -301851 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -4827188 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1356383 Filing: 000119312526134897 Input fundies:OperatingCashFlow: -4525337 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1358367 Filing: 000119312526134897
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 0
Operating costs Derived USD 31.84 million
Operating income −USD 31.84 million
Tax, interest and other Derived −USD 233,184
Net income −USD 31.61 million

Cash

Operating cash flow −USD 17.6 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 4,047% of revenue.
2017 Operating loss: operating costs were 194% of revenue.
2018 Operating loss: operating costs were 186% of revenue.
2019 Operating loss: operating costs were 339% of revenue.
2020 Operating loss: operating costs were 249% of revenue.
2021 Operating loss: operating costs were 796% of revenue.
2022 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	1010663	40896895 Derived	-39886232	-393109 Derived	-39493123	-32611491 Derived	Source 2016-01-01 – 2016-12-31: 1010663 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -39886232 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -39493123 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -32052113 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 559378 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	1851892	3600739 Derived	-1748847	-1512 Derived	-1747335	-1569674 Derived	Source 2017-01-01 – 2017-12-31: 1851892 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -1748847 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -1747335 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -1456176 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 113498 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	1951351	3635982 Derived	-1684631	-14994 Derived	-1669637	4177189 Derived	Source 2018-01-01 – 2018-12-31: 1951351 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -1684631 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -1669637 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 4177189 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 0 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	3465055	11730132 Derived	-8265077	-1328814 Derived	-6936263	-11580096 Derived	Source 2019-01-01 – 2019-12-31: 3465055 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -8265077 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -6936263 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -11580096 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 0 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	5233301	13019646 Derived	-7786345	-434091 Derived	-7352254	-10313963 Derived	Source 2020-01-01 – 2020-12-31: 5233301 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -7786345 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -7352254 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -10311363 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 2600 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1840216	14653147 Derived	-12812931	-44693 Derived	-12768238	-10200197 Derived	Source 2021-01-01 – 2021-12-31: 1840216 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -12812931 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -12768238 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -10200197 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	0	31841140 Derived	-31841140	-233184 Derived	-31607956	Unavailable	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -31841140 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -31607956 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -17595321 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	0	Revenue: 0 Open source
20162016-12-31	Revenue	1010663	Revenue: 1010663 Open source
20172017-12-31	Revenue	1851892	Revenue: 1851892 Open source
20182018-12-31	Revenue	1951351	Revenue: 1951351 Open source
20192019-12-31	Revenue	3465055	Revenue: 3465055 Open source
20202020-12-31	Revenue	5233301	Revenue: 5233301 Open source
20212021-12-31	Revenue	1840216	Revenue: 1840216 Open source
20222022-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20162016-12-31	Year over year	No prior comparable period	Revenue: 1010663 Open source Revenue: 0 Open source
20172017-12-31	Year over year	83.2%	Revenue: 1851892 Open source Revenue: 1010663 Open source
20182018-12-31	Year over year	5.4%	Revenue: 1951351 Open source Revenue: 1851892 Open source
20192019-12-31	Year over year	77.6%	Revenue: 3465055 Open source Revenue: 1951351 Open source
20202020-12-31	Year over year	51%	Revenue: 5233301 Open source Revenue: 3465055 Open source
20212021-12-31	Year over year	-64.8%	Revenue: 1840216 Open source Revenue: 5233301 Open source
20222022-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 1840216 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -696.3% 2021

Net margin -693.8% 2021

Free cash flow margin -554.3% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	Not reported	Operating Income: -29213658 Open source Revenue: 0 Open source
20162016-12-31	Operating margin	-3,946.5%	Operating Income: -39886232 Open source Revenue: 1010663 Open source
20172017-12-31	Operating margin	-94.4%	Operating Income: -1748847 Open source Revenue: 1851892 Open source
20182018-12-31	Operating margin	-86.3%	Operating Income: -1684631 Open source Revenue: 1951351 Open source
20192019-12-31	Operating margin	-238.5%	Operating Income: -8265077 Open source Revenue: 3465055 Open source
20202020-12-31	Operating margin	-148.8%	Operating Income: -7786345 Open source Revenue: 5233301 Open source
20212021-12-31	Operating margin	-696.3%	Operating Income: -12812931 Open source Revenue: 1840216 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -31841140 Open source Revenue: 0 Open source
20152015-12-31	Net margin	Not reported	Net Income: -29141630 Open source Revenue: 0 Open source
20162016-12-31	Net margin	-3,907.6%	Net Income: -39493123 Open source Revenue: 1010663 Open source
20172017-12-31	Net margin	-94.4%	Net Income: -1747335 Open source Revenue: 1851892 Open source
20182018-12-31	Net margin	-85.6%	Net Income: -1669637 Open source Revenue: 1951351 Open source
20192019-12-31	Net margin	-200.2%	Net Income: -6936263 Open source Revenue: 3465055 Open source
20202020-12-31	Net margin	-140.5%	Net Income: -7352254 Open source Revenue: 5233301 Open source
20212021-12-31	Net margin	-693.8%	Net Income: -12768238 Open source Revenue: 1840216 Open source
20222022-12-31	Net margin	Not reported	Net Income: -31607956 Open source Revenue: 0 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source
20162016-12-31	Free cash flow margin	-3,226.7%	Revenue: 1010663 Open source Operating Cash Flow: -32052113 Open source Capital Expenditure: 559378 Open source
20172017-12-31	Free cash flow margin	-84.8%	Revenue: 1851892 Open source Operating Cash Flow: -1456176 Open source Capital Expenditure: 113498 Open source
20182018-12-31	Free cash flow margin	214.1%	Revenue: 1951351 Open source Operating Cash Flow: 4177189 Open source Capital Expenditure: 0 Open source
20192019-12-31	Free cash flow margin	-334.2%	Revenue: 3465055 Open source Operating Cash Flow: -11580096 Open source Capital Expenditure: 0 Open source
20202020-12-31	Free cash flow margin	-197.1%	Revenue: 5233301 Open source Operating Cash Flow: -10311363 Open source Capital Expenditure: 2600 Open source
20212021-12-31	Free cash flow margin	-554.3%	Revenue: 1840216 Open source Operating Cash Flow: -10200197 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -17595321 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -17.6M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	-32052113	Operating Cash Flow: -32052113 Open source
20172017-12-31	Operating cash flow	-1456176	Operating Cash Flow: -1456176 Open source
20182018-12-31	Operating cash flow	4177189	Operating Cash Flow: 4177189 Open source
20192019-12-31	Operating cash flow	-11580096	Operating Cash Flow: -11580096 Open source
20202020-12-31	Operating cash flow	-10311363	Operating Cash Flow: -10311363 Open source
20212021-12-31	Operating cash flow	-10200197	Operating Cash Flow: -10200197 Open source
20222022-12-31	Operating cash flow	-17595321	Operating Cash Flow: -17595321 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -10.2M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	-32611491	Operating Cash Flow: -32052113 Open source Capital Expenditure: 559378 Open source
20172017-12-31	Free cash flow	-1569674	Operating Cash Flow: -1456176 Open source Capital Expenditure: 113498 Open source
20182018-12-31	Free cash flow	4177189	Operating Cash Flow: 4177189 Open source Capital Expenditure: 0 Open source
20192019-12-31	Free cash flow	-11580096	Operating Cash Flow: -11580096 Open source Capital Expenditure: 0 Open source
20202020-12-31	Free cash flow	-10313963	Operating Cash Flow: -10311363 Open source Capital Expenditure: 2600 Open source
20212021-12-31	Free cash flow	-10200197	Operating Cash Flow: -10200197 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -17595321 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

29.1% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	3%	Total Liabilities: 2877430 Open source Total Assets: 95069838 Open source
20162016-12-31	Liabilities / assets	6.2%	Total Liabilities: 3897593 Open source Total Assets: 63214979 Open source
20172017-12-31	Liabilities / assets	249.6%	Total Liabilities: 1722025 Open source Total Assets: 690043 Open source
20182018-12-31	Liabilities / assets	119.2%	Total Liabilities: 7884937 Open source Total Assets: 6613823 Open source
20192019-12-31	Liabilities / assets	23.8%	Total Liabilities: 3313544 Open source Total Assets: 13894398 Open source
20202020-12-31	Liabilities / assets	11.1%	Total Liabilities: 2773133 Open source Total Assets: 24932321 Open source
20212021-12-31	Liabilities / assets	5.2%	Total Liabilities: 2110883 Open source Total Assets: 40833868 Open source
20222022-12-31	Liabilities / assets	29.1%	Total Liabilities: 4266191 Open source Total Assets: 14650799 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.76× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	32.4×	Current Assets: 92247617 Open source Current Liabilities: 2847401 Open source
20162016-12-31	Current assets / current liabilities	16.06×	Current Assets: 62467269 Open source Current Liabilities: 3889195 Open source
20172017-12-31	Current assets / current liabilities	0.09×	Current Assets: 528883 Open source Current Liabilities: 5847670 Open source
20182018-12-31	Current assets / current liabilities	5.76×	Current Assets: 6380867 Open source Current Liabilities: 1106870 Open source
20192019-12-31	Current assets / current liabilities	Not reported	Current Assets: 4694799 Open source
20202020-12-31	Current assets / current liabilities	Not reported	Current Assets: 15796660 Open source
20212021-12-31	Current assets / current liabilities	Not reported	Current Assets: 30163595 Open source
20222022-12-31	Current assets / current liabilities	Not reported	Current Assets: 14520298 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 39.49 million Exact value Exact value: -39493123 USD 2016-01-01 – 2016-12-31: -39493123 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2016-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -39493123 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39493123 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#226517 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.	−USD 32.05 million Exact value Exact value: -32052113 USD 2016-01-01 – 2016-12-31: -32052113 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2016-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -32052113 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32052113 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#225884 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.	USD 559,378 Exact value Exact value: 559378 USD 2016-01-01 – 2016-12-31: 559378 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SALARIUS PHARMACEUTICALS, INC. · 2016-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Capital Expenditure: 559378 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 559378 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#240472 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.	−USD 32.61 million Calculation and evidence -32052113 − 559378 USD Exact free cash flow: -32611491 USD 2016-01-01 – 2016-12-31: -32052113 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 559378 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SALARIUS PHARMACEUTICALS, INC. · 2016-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Free cash flow: -32611491 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32052113 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#225884 Filing: 000161521919000008 Input fundies:CapitalExpenditure: 559378 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#240472 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 1.75 million Exact value Exact value: -1747335 USD 2017-01-01 – 2017-12-31: -1747335 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2017-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -1747335 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1747335 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312520005401/slrx-20181231.xml#39353 Filing: 000119312520005401 The citation records this snapshot. The page link may show a newer release later.	−USD 1.46 million Exact value Exact value: -1456176 USD 2017-01-01 – 2017-12-31: -1456176 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2017-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -1456176 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1456176 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312520005401/slrx-20181231.xml#42084 Filing: 000119312520005401 The citation records this snapshot. The page link may show a newer release later.	USD 113,498 Exact value Exact value: 113498 USD 2017-01-01 – 2017-12-31: 113498 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SALARIUS PHARMACEUTICALS, INC. · 2017-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Capital Expenditure: 113498 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 113498 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#240680 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.	−USD 1.57 million Calculation and evidence -1456176 − 113498 USD Exact free cash flow: -1569674 USD 2017-01-01 – 2017-12-31: -1456176 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 113498 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SALARIUS PHARMACEUTICALS, INC. · 2017-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Free cash flow: -1569674 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1456176 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312520005401/slrx-20181231.xml#42084 Filing: 000119312520005401 Input fundies:CapitalExpenditure: 113498 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#240680 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 1.67 million Exact value Exact value: -1669637 USD 2018-01-01 – 2018-12-31: -1669637 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2018-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -1669637 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1669637 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521920000014/flks-20191231.htm#951943 Filing: 000161521920000014 The citation records this snapshot. The page link may show a newer release later.	USD 4.18 million Exact value Exact value: 4177189 USD 2018-01-01 – 2018-12-31: 4177189 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2018-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: 4177189 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4177189 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521920000014/flks-20191231.htm#849225 Filing: 000161521920000014 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2018-01-01 – 2018-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SALARIUS PHARMACEUTICALS, INC. · 2018-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#240888 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.	USD 4.18 million Calculation and evidence 4177189 − 0 USD Exact free cash flow: 4177189 USD 2018-01-01 – 2018-12-31: 4177189 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SALARIUS PHARMACEUTICALS, INC. · 2018-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Free cash flow: 4177189 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4177189 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521920000014/flks-20191231.htm#849225 Filing: 000161521920000014 Input fundies:CapitalExpenditure: 0 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521919000008/flks-20181231.xml#240888 Filing: 000161521919000008 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 6.94 million Exact value Exact value: -6936263 USD 2019-01-01 – 2019-12-31: -6936263 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2019-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -6936263 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6936263 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521921000026/flks-20201231.htm#831041 Filing: 000161521921000026 The citation records this snapshot. The page link may show a newer release later.	−USD 11.58 million Exact value Exact value: -11580096 USD 2019-01-01 – 2019-12-31: -11580096 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2019-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -11580096 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11580096 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521921000026/flks-20201231.htm#738735 Filing: 000161521921000026 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2019-01-01 – 2019-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SALARIUS PHARMACEUTICALS, INC. · 2019-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521921000026/flks-20201231.htm#741724 Filing: 000161521921000026 The citation records this snapshot. The page link may show a newer release later.	−USD 11.58 million Calculation and evidence -11580096 − 0 USD Exact free cash flow: -11580096 USD 2019-01-01 – 2019-12-31: -11580096 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SALARIUS PHARMACEUTICALS, INC. · 2019-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Free cash flow: -11580096 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11580096 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521921000026/flks-20201231.htm#738735 Filing: 000161521921000026 Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521921000026/flks-20201231.htm#741724 Filing: 000161521921000026 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 7.35 million Exact value Exact value: -7352254 USD 2020-01-01 – 2020-12-31: -7352254 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2020-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -7352254 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7352254 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000028/flks-20211231.htm#875711 Filing: 000161521922000028 The citation records this snapshot. The page link may show a newer release later.	−USD 10.31 million Exact value Exact value: -10311363 USD 2020-01-01 – 2020-12-31: -10311363 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2020-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -10311363 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10311363 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000028/flks-20211231.htm#785343 Filing: 000161521922000028 The citation records this snapshot. The page link may show a newer release later.	USD 2,600 Exact value Exact value: 2600 USD 2020-01-01 – 2020-12-31: 2600 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SALARIUS PHARMACEUTICALS, INC. · 2020-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Capital Expenditure: 2600 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2600 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000028/flks-20211231.htm#788342 Filing: 000161521922000028 The citation records this snapshot. The page link may show a newer release later.	−USD 10.31 million Calculation and evidence -10311363 − 2600 USD Exact free cash flow: -10313963 USD 2020-01-01 – 2020-12-31: -10311363 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2600 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SALARIUS PHARMACEUTICALS, INC. · 2020-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Free cash flow: -10313963 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10311363 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000028/flks-20211231.htm#785343 Filing: 000161521922000028 Input fundies:CapitalExpenditure: 2600 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000028/flks-20211231.htm#788342 Filing: 000161521922000028 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 12.77 million Exact value Exact value: -12768238 USD 2021-01-01 – 2021-12-31: -12768238 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2021-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -12768238 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12768238 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000030/flks-20221231.htm#793515 Filing: 000161521923000030 The citation records this snapshot. The page link may show a newer release later.	−USD 10.2 million Exact value Exact value: -10200197 USD 2021-01-01 – 2021-12-31: -10200197 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2021-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -10200197 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10200197 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000030/flks-20221231.htm#742144 Filing: 000161521923000030 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SALARIUS PHARMACEUTICALS, INC. · 2021-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000028/flks-20211231.htm#787363 Filing: 000161521922000028 The citation records this snapshot. The page link may show a newer release later.	−USD 10.2 million Calculation and evidence -10200197 − 0 USD Exact free cash flow: -10200197 USD 2021-01-01 – 2021-12-31: -10200197 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SALARIUS PHARMACEUTICALS, INC. · 2021-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Free cash flow: -10200197 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10200197 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000030/flks-20221231.htm#742144 Filing: 000161521923000030 Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000028/flks-20211231.htm#787363 Filing: 000161521922000028 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 31.61 million Exact value Exact value: -31607956 USD 2022-01-01 – 2022-12-31: -31607956 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2022-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -31607956 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31607956 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000162828025001947/flks-20250121.htm#2506112 Filing: 000162828025001947 The citation records this snapshot. The page link may show a newer release later.	−USD 17.6 million Exact value Exact value: -17595321 USD 2022-01-01 – 2022-12-31: -17595321 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2022-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -17595321 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17595321 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000162828025001947/flks-20250121.htm#2459569 Filing: 000162828025001947 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 12.54 million Exact value Exact value: -12542693 USD 2023-01-01 – 2023-12-31: -12542693 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2023-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -12542693 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12542693 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000037/flks-20241231.htm#581989 Filing: 000161521925000037 The citation records this snapshot. The page link may show a newer release later.	−USD 12.85 million Exact value Exact value: -12846137 USD 2023-01-01 – 2023-12-31: -12846137 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2023-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -12846137 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12846137 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000037/flks-20241231.htm#545098 Filing: 000161521925000037 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 5.58 million Exact value Exact value: -5575777 USD 2024-01-01 – 2024-12-31: -5575777 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2024-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -5575777 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5575777 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1488956 Filing: 000119312526134897 The citation records this snapshot. The page link may show a newer release later.	−USD 4.53 million Exact value Exact value: -4525337 USD 2024-01-01 – 2024-12-31: -4525337 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2024-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -4525337 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4525337 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1358367 Filing: 000119312526134897 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 12.52 million Exact value Exact value: -12518480 USD 2025-01-01 – 2025-12-31: -12518480 USD Inspect Net Income Open source Share or cite Citation for Net Income · SALARIUS PHARMACEUTICALS, INC. · 2025-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Net Income: -12518480 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12518480 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1543807 Filing: 000119312526134897 The citation records this snapshot. The page link may show a newer release later.	−USD 4.83 million Exact value Exact value: -4827188 USD 2025-01-01 – 2025-12-31: -4827188 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SALARIUS PHARMACEUTICALS, INC. · 2025-12-31 SALARIUS PHARMACEUTICALS, INC. (edgar:1615219) Operating Cash Flow: -4827188 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1615219/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4827188 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1615219/000119312526134897/dcoy-20251231.htm#1356383 Filing: 000119312526134897 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

70 filings · 2,950 latest values · 2,950 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001615219, 1615219, DCOY, FLKS, SLRX, edgar:1615219

Also known as DECOY THERAPEUTICS INC., Decoy Therapeutics Inc., Flex Pharma, Inc., SALARIUS PHARMACEUTICALS, INC., SALARIUS PHARMACEUTICALS, INC., Salarius Pharmaceuticals, Inc.

SALARIUS PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation